Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Amit Gupta sold 68,260 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $1.12, for a total value of $76,451.20. Following the completion of the sale, the chief executive officer owned 560,444 shares of the company's stock, valued at $627,697.28. This trade represents a 10.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Amit Gupta also recently made the following trade(s):
- On Tuesday, August 19th, Amit Gupta sold 68,685 shares of Cardlytics stock. The stock was sold at an average price of $1.12, for a total transaction of $76,927.20.
- On Wednesday, July 2nd, Amit Gupta sold 6,725 shares of Cardlytics stock. The stock was sold at an average price of $1.78, for a total transaction of $11,970.50.
Cardlytics Stock Performance
Shares of Cardlytics stock traded down $0.0250 on Tuesday, hitting $1.10. The stock had a trading volume of 1,612,532 shares, compared to its average volume of 2,324,776. Cardlytics, Inc. has a 52-week low of $1.0338 and a 52-week high of $5.2450. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 2.87. The stock has a market cap of $58.56 million, a price-to-earnings ratio of -0.30 and a beta of 1.26. The company's 50 day moving average price is $1.77 and its 200 day moving average price is $2.00.
Analysts Set New Price Targets
A number of research analysts have recently commented on CDLX shares. Lake Street Capital dropped their price objective on shares of Cardlytics from $3.00 to $2.50 and set a "hold" rating for the company in a research note on Thursday, May 8th. Evercore ISI dropped their price objective on Cardlytics from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cardlytics has an average rating of "Moderate Buy" and an average price target of $2.25.
Check Out Our Latest Report on CDLX
Institutional Investors Weigh In On Cardlytics
Several institutional investors and hedge funds have recently modified their holdings of CDLX. Geode Capital Management LLC boosted its holdings in Cardlytics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock valued at $3,936,000 after purchasing an additional 7,561 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Cardlytics by 46.0% in the 4th quarter. Wells Fargo & Company MN now owns 21,106 shares of the company's stock valued at $78,000 after acquiring an additional 6,649 shares in the last quarter. Barclays PLC increased its position in shares of Cardlytics by 26.2% during the 4th quarter. Barclays PLC now owns 73,255 shares of the company's stock worth $272,000 after purchasing an additional 15,229 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Cardlytics during the 4th quarter worth approximately $157,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Cardlytics during the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 68.10% of the company's stock.
About Cardlytics
(
Get Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardlytics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.
While Cardlytics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.